Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
After finishing at $7.11 in the prior trading day, G1 Therapeutics Inc (NASDAQ: GTHX) closed at $7.09, down -0.28%. In other words, the price has decreased by -$0.28 from its previous closing price. On the day, 2.85 million shares were traded. GTHX stock price reached its highest trading level at $7.12 during the session, while it also had its lowest trading level at $7.08.
Ratios:
Our goal is to gain a better understanding of GTHX by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.12 and its Current Ratio is at 2.48. In the meantime, Its Debt-to-Equity ratio is 1.95 whereas as Long-Term Debt/Eq ratio is at 1.49.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, JP Morgan on January 30, 2023, Upgraded its rating to Neutral and sets its target price to $10 from $7 previously.
On January 03, 2023, Needham reiterated its Buy rating and also upped its target price recommendation from $32 to $31.
JP Morgan Downgraded its Neutral to Underweight on November 04, 2021, whereas the target price for the stock was revised from $20 to $19.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jul 05 ’24 when Perry Andrew sold 1,337 shares for $2.51 per share. The transaction valued at 3,353 led to the insider holds 112,614 shares of the business.
MURDOCK TERRY L sold 2,475 shares of GTHX for $6,207 on Jul 05 ’24. The Chief Operating Officer now owns 128,012 shares after completing the transaction at $2.51 per share. On Jul 05 ’24, another insider, Malik Rajesh, who serves as the Chief Medical Officer of the company, sold 2,475 shares for $2.51 each. As a result, the insider received 6,207 and left with 159,312 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, GTHX now has a Market Capitalization of 375110624 and an Enterprise Value of 361289568. For the stock, the TTM Price-to-Sale (P/S) ratio is 6.37 while its Price-to-Book (P/B) ratio in mrq is 15.19. Its current Enterprise Value per Revenue stands at 6.208 whereas that against EBITDA is -9.663.
Stock Price History:
Over the past 52 weeks, GTHX has reached a high of $7.12, while it has fallen to a 52-week low of $1.08. The 50-Day Moving Average of the stock is 88.73%, while the 200-Day Moving Average is calculated to be 105.44%.
Shares Statistics:
The stock has traded on average 1.90M shares per day over the past 3-months and 6124940 shares per day over the last 10 days, according to various share statistics. A total of 51.93M shares are outstanding, with a floating share count of 42.79M. Insiders hold about 18.15% of the company’s shares, while institutions hold 38.45% stake in the company. Shares short for GTHX as of 1722384000 were 5769247 with a Short Ratio of 3.03, compared to 1719532800 on 5693103. Therefore, it implies a Short% of Shares Outstanding of 5769247 and a Short% of Float of 11.05.
